Assess
Review current program state, constraints, interdependencies, and the decisions most likely to shape near-term progress. Identify where structure is missing and where execution risk is highest.
Built for emerging biotech, pharma development teams, and medical device companies that need experienced program leadership — without the overhead of a full-time hire.
Emerging Biotech·Pharma Operations·Medical Device & 510(k)/PMA
In memory of Dr. John Fontana
Fresh out of my MBA, I joined my first startup, NanoCoeur Inc., alongside its founder, Dr. John Fontana. It was one of the luckiest breaks of my career. John wasn't just a boss — he became a mentor who stayed by my side for years, celebrating everything from my graduation to my wedding.
Two years ago, I spoke with him after his surgery. As I tried to cheer him up by asking about our next big startup idea, he said something I'd never heard him say before: "I don't know, not this time…" A few months later, he was gone. Because I never got that final visit he asked for, I felt a lack of closure — like something had been left unfinished.
Before he passed, John handed me the reins — wanting to ensure the spirit of the idea lived on. Choosing to name this firm NanoCoeur was a deeply personal decision. This name represents more than a business; it is a commitment to the same innovation and grit I witnessed with John fifteen years ago.
NanoCoeur Consulting brings that agile, entrepreneurial spirit to organizations seeking strategic operations expertise across the life sciences product development lifecycle.
Life Sciences Program Management Consultant · Fractional PMO · Serving clients nationwide
Life sciences program management consultant with 15+ years advancing drug development, medical device, and IVD programs from early R&D through commercialization. Across oncology, orthopedics, diagnostics, and blood products, Ihab has built PMOs from the ground up, secured FDA IND approvals, led partnerships with global diagnostics and device organizations, and guided cross-functional teams through the full product lifecycle.
His fractional PMO engagements have delivered measurable outcomes in funding readiness, operational efficiency, and regulatory performance for clients ranging from early-stage biotech startups to publicly traded life sciences companies — with active AI integration work spanning governance, workflow automation, and executive decision enablement.
Start a conversation →NanoCoeur brings experienced program leadership to the moments where structure, alignment, and execution discipline make the biggest difference — across biotech, pharma, and medical device development.
Fifteen-plus years of hands-on program experience across the organizations that set the standard in life sciences — medical device development with Boston Scientific, Medtronic, Johnson & Johnson, and Smith & Nephew; diagnostics and hemostasis programs with Abbott, Siemens, and Haemonetics; clinical and program execution across global pharmaceutical and biotechnology organizations; and operational delivery with partners including LabCorp, ICON, and Syneos Health.
That's the foundation NanoCoeur brings to your programs today — the same agile discipline, the same intolerance for imprecision, applied across the full development lifecycle, from early R&D through commercialization.
Review current program state, constraints, interdependencies, and the decisions most likely to shape near-term progress. Identify where structure is missing and where execution risk is highest.
Clarify priorities, ownership, governance, and the execution path for stronger readiness and fewer cross-functional blind spots. Resolve the interdependencies that slow programs before they become crises.
Provide hands-on program leadership and execution support where discipline, visibility, and momentum are needed most — from milestone planning through regulatory submission and commercial readiness.
Engagements range from targeted strategic support around a single milestone to hands-on leadership across planning, governance, and execution — scoped to what your program actually needs.
Focused perspectives on the operating challenges that matter most — also shared on LinkedIn.
May 13, 2026
NanoCoeur supports biotech, pharma, and medical device teams navigating complex milestones across the full development lifecycle. For consulting inquiries, introductions, or referred opportunities, use the form to get in touch.
Share a few details and we'll follow up to discuss fit.